HIV Prevention Trials Network: Network Laboratory

超出空间 但前提是。 艾滋病毒预防试验网络(HPTN)的使命是发现和开发能够 在全球范围内用于预防艾滋病毒的性传播和/或非肠道传播。我们的研究包括 测试新的生物医学和行为方法。我们寻求有效的艾滋病毒预防策略， 安全、可行和可持续，即使在资源有限的情况下也是如此。现任HPTN已经建立了现场站点 16个发展中国家的研究能力。在国际HIVNET和HPTN中，我们招募了 31,250名艾滋病毒未感染者(主要是)和感染者参加38次试验(19,500人由现任HPTN自 1999年)。受试者几乎都是高危人群，包括青少年和急性感染者。 重点关注非洲、亚洲等资源紧缺的国家。美国和东欧，以及高 在美国，我们的最高影响试验确实改变了全球公共卫生 如HIVNET 012预防母婴传播艾滋病毒的做法。我们正在划分 目前的HPTN议程分为三部分，我们的围产期小组合作创建IMPAACT和 杀微生物剂集团带头生产MTN。因此，新的HPTN焦点有四个方面：(1)抗逆转录病毒治疗和 减少病毒载量和预防艾滋病毒传播的联合感染疗法；(2)性传播疾病的治疗 传播感染(STI)，以降低艾滋病毒传播风险；(3)治疗药物滥用和成瘾， 包括注射吸毒和兴奋剂(可卡因和甲基苯丙胺)，以减少艾滋病毒传播； 以及(4)通过生物终点降低行为风险。我们对HIV病毒使用随机对照试验 未感染者的发病终点。在急性和慢性艾滋病毒患者中进行预防研究- ，我们研究了非HIV性传播感染的发病率、HIV病毒载量的降低和/或HIV在 性伴侣或共用针头的伴侣。我们建议完成五项正在进行的HPTN试验，并将 如果得到资助，在IMPAACT和MTN网络上增加6个正在进行的HPTN试验。我们提出了八项新的试验 五个用于预防艾滋病毒感染的概念，一个用于在急性感染者中进行检测和干预 其中两个侧重于艾滋病毒血清阳性者的预防。我们的风险 人群包括高危异性恋者、男男性行为者、滥用药物者，以及 选定的试验，他们的性伴侣或共用针头的伴侣。我们建议的附属临床试验单位提供以下服务- 五大洲的风险人群，特别是撒哈拉以南非洲和美国HPTN领导小组 是经验丰富和多样化的，包括经验丰富的道德专家和社区领袖。HPTN 治理旨在高效地开发和完成试验。我们强调高潜力的概念 对公共健康的影响，重点是可以立即付诸实践的现有技术。 因此，我们的议程是对长期投资(寻找治愈方法、疫苗或杀微生物剂)的补充。

EXCEED THE SPACE PROVIDED. The mission of the HIV Prevention Trials Network (HPTN) is to discover and develop interventions that can be used globally to prevent sexual and/or parenteral transmission of HIV. Our research encompasses the testing of novel biomedical and behavioral approaches. We seek HIV prevention strategies that are effective, safe, feasible, and sustainable, even in resource-limited settings. The incumbent HPTN has built field site research capacity in 16 developing countries. In the International HIVNET and the HPTN, we have recruited 31,250 HIV uninfected (principally) and infected persons into 38 trials (19,500 by the incumbent HPTN since 1999). Subjects are almost exclusively high risk, including adolescents and acutely infected persons. Focusing on resource-constrained countries in Africa, Asia, So. America, and E. Europe, as well as high incidence populations in the U.S., our highest impact trials have literally changed global public health practice, as with HIVNET 012 for the prevention of mother-to-infant HIV transmission. We are dividing the current HPTN agenda into three parts, our perinatal group partnering to create IMPAACT and the microbicide group spearheading MTN. Hence, the new HPTN focus is fourfold: (1) antiretroviral therapy and co-infection therapy for viral load reduction and prevention of HIV transmission; (2) treatment of sexually transmitted infections (STI) to lower HIV transmission risk; (3) treatment of substance abuse and addiction, including injection drug use and stimulants (cocaine and methamphetamines) to reduce HIV transmission; and (4) behavioral risk reduction with biological endpoints. We use randomized controlled trials with HIV incidence endpoints in uninfected persons. For prevention research among acutely and chronically HIV- infected persons, we study incidence of non-HIV STIs, lowering of HIV viral load, and/or HIV incidence in sexual or needle-sharing partners. We propose to complete five ongoing HPTN trials and to transition an additional six ongoing HPTN trials to IMPAACT and MTN networks, if funded. We present eight new trial concepts, five for prevention of HIV infection, one for detection and intervention among acutely infected persons (pre-seroconversion), and two focused on prevention among HIV-seropositive persons. Our risk populations include high risk heterosexuals, men who have sex with men, substance abusers, and, for selected trials, their sexual or needle-sharing partners. Our proposed affiliated Clinical Trials Units serve at- risk populations on five continents, especially sub-Saharan Africa and the U.S. The HPTN Leadership Group is experienced and diverse and includes experienced ethics experts and community leaders. HPTN governance is designed to develop and complete trials efficiently. We emphasize concepts of high potential public health impact, focusing on existing technologies that can be brought immediately into practice. Therefore, our agenda is complementary to long-term investments (finding a cure, vaccine, or microbicide).